A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Palmoplantar Psoriasis
Latest Information Update: 12 Jul 2019
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms GESTURE
- Sponsors Novartis
- 08 Jul 2019 Sustained efficacy results over 2.5 years were published in the British Journal of Dermatology.
- 17 Jun 2019 According to a novartis media release, pooled data from SCULPTURE, ERASURE/FIXTURE, TRANSFIGURE, GESTURE, FUTURE 2 and MEASURE 2 studies were presented at the World Congress of Dermatology 2019.
- 30 Nov 2017 According to a Novartis media release, data from the study has been presented at the 8th International Congress of Psoriasis from Gene to Clinic 2017.